Abstract: A cancer has a DNA methylation signature in host T cells and Peripheral Blood Mononuclear Cells (PBMC) DNA. The present disclosure provides CG IDs derived from PBMC DNA for predicting hepatocellular carcinoma (HCC) stages and chronic hepatitis. Also disclosed are kits for predicting HCC using identified CG IDs and pyrosequencing DNA methylation assays, receiver operating characteristics (ROC) assays, penalized regression assays and hierarchical clustering analysis assays. The present disclosure provides DNA methylation signatures (CG IDs) that can be used for diagnosis, prognosis, and treatment of a cancer.

Abstract: The present invention relates to method for calculating biological age of a subject and across multiple subjects by performing polygenic DNA methylation on biomarkers which comprise measuring the methylation status of 13 CG sites positioned in a putative antisense region to ElovL2 gene, ElovL2 AS1 region. Further, the present invention provides a computer-implemented method for providing recommendations for lifestyle changes in form of a self-learning “ecosystem” for lifestyle management of biological aging using a novel measurement of the DNA methylation clock as a continuous dynamic outcome. The present invention also relates to combination of DNA methylation biomarkers for calculating biological age, a kit for determining the biological age. Further, the present invention discloses the use of the disclosed methods for calculating biological age in a method of assessing the effect of the effect of a biological intervention and in a method of screening for an anti-ageing agent.

Abstract: The present invention discloses an in vitro method for obtaining DNA methylation biomarkers as exquisite DNA methylation positions in the human genome (i.e., CGIDs) that predict cervical cancer especially at as yet inaccessible early stages by examining progression of “categorical” DNA methylation alterations in three stages of premalignant lesions (cervical intraepithelial neoplasia (CIN)), progressing from CIN1 to CIN3. The present invention discloses combinations of CGIDs for detecting with high specificity and sensitivity cervical cancer by measuring their DNA methylation status and deriving a “methylation score”, which is useful as a biomarker for cervical cancer. Also disclosed are kits for predicting cervical cancer using such CGIDs using multiplexed next generation sequencing methylation assays, pyrosequencing assays and methylation specific PCR.

Abstract: Disclosed is a DNA methylation signature in Peripheral Blood Mononuclear cells (PBMC) for predicting hepatocellular carcinoma (HCC) stages and chronic hepatitis, which is CG IDs. This invention also disclosed kits and uses for the DNA methylation signature.

Abstract: Methods regarding DNA methylation signature of post-traumatic stress disorder (PTSD) in brains of susceptible, resilient animals methylated in response to trauma, and S-adensoyl methionine (SAM) treated animals for deriving targets for PTSD therapeutics. Method regarding pathway analysis of the DNA methylation landscape to derive novel targets for therapeutic interventions such as retinoic acid pathway or estrogen receptor pathways. A method of treatment of PTSD comprised of Epigenetic modulators using general DNA methylation modulators such as SAM. A method of treatment of PTSD comprised of retinoic acid or vitamin A and its natural and synthetic analogs such as all-trans-retinoic acid (Tretinoin), 9-cis-retinoic acid (Alitretinoin), and 13-cis-retinoic acid (Isotretinoin) to treat PTSD. A method of treatment of PTSD comprised of a combination of Sadenosylmethionine and retinoic acid or vitamin A and its synthetic and natural analogs such as Tretinoin, Alitretinoin, and Isotretinoin.

Abstract: Oligonucleotide inhibitors that inhibit expression of a mammalian MBD2/DNA demethylase (MBD2/dMTase) are provided. The oligonucleotide inhibitors can be used to inhibit the growth or proliferation of tumor cells in vitro and in vivo. The use of the oligonucleotide inhibitors in the treatment of cancer and methods of identifying potential target genes for cancer therapy or diagnosis using the oligonucleotide inhibitors are also provided.

Abstract: The present invention relates to a DNA demethylase enzyme having about 40 KDa, and wherein said DNA demethylase enzyme is overexpressed in cancer cells and not in normal cells. The present invention also relates to the therapeutic and diagnostic uses of the DNA demethylase.

Abstract: Oligonucleotide inhibitors that inhibit expression of a mammalian MBD2/DNA demethylase (MBD2/dMTase) are provided. The oligonucleotide inhibitors can be used to inhibit the growth or proliferation of tumour cells in vitro and in vivo. The use of the oligonucleotide inhibitors in the treatment of cancer and methods of identifying potential target genes for cancer therapy or diagnosis using the oligonucleotide inhibitors are also provided.

Abstract: The present invention relates to a DNA demethylase (dMTase) inhibitor which comprises s-adenosylmethionine, a metabolite of s-adenosylmethionine or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to the interplay between the level of DNA methyltransferase and demethylase activities, to the role of the interplay between these levels on the proliferative, differentiated, tumorigenic and homeostatic state of the cell, and to the DNA methyltransferase and demethylase as therapeutic targets.

Abstract: The invention provides novel mechanism-based inhibitors of DNA methyltransferase enzyme, and diagnostic and therapeutic uses for the same. The novel inhibitors according to the invention form stable, noncovalent complexes with DNA methyltransferase enzyme in a manner which is independent of S-adenosylmethionine.

Abstract: The invention provides novel mechanism-based inhibitors of DNA methyltransferase enzyme, and diagnostic and therapeutic uses for the same. The novel inhibitors according to the invention form stable, noncovalent complexes with DNA methyltransferase enzyme in a manner which is independent of S-adenosylmethionine.

Abstract: The invention provides recombinant nucleic acids comprising nucleic acid sequences from the genomic DNA methyltransferase gene. The invention further provides sequence information for such nucleic acid sequences. In addition, the invention provides antisense oligonucleotides complementary to special regions of the genomic DNA methyltransferase gene or its RNA transcript. Finally, the invention provides methods for using such antisense oligonucleotides as analytical and diagnostic tools, as potentiators of transgenic plant and animal studies and gene therapy approaches, and as potential therapeutic agents.

Abstract: The present invention relates to the interplay between the level of DNA methyltransferase and demethylase activities, to the role of the interplay between these levels on the proliferative, differentiated, tumorigenic and homeostatic state of the cell, and to the DNA methyltransferase and demethylase as therapeutic targets. The invention further relates to a reduction of the level of DNA methylation through inhibitors and antagonist in order to inhibit the excessive activity or hypermethylation of DNA MeTase in cancer cells to induce the original cellular tumor suppressing program, to turn on alternative gene expression programs, to provide therapeutics directed at a nodal point of regulation of genetic information, and to modulate the general level of methylase and demethylase enzymatic activity of a cell to permit specific changes in the methylation pattern of a cell.

Abstract: The invention encompasses tumorigenicity-inhibiting antisense oligonucleotide sequences complementary to mRNA or double-stranded DNA that encodes mammalian DNA methyl transferase. It further encompasses methods for inhibiting tumorigenicity and pharmaceutical composition comprising the tumorigenicity-inhibiting antisense nucleotide.

Abstract: The invention provides recombinant nucleic acids comprising nucleic acid sequences from the genomic DNA methyltransferase gene. The invention further provides sequence information for such nucleic acid sequences. In addition, the invention provides antisense oligonucleotides complementary to special regions of the genomic DNA methyltransferase gene or its RNA transcript. Finally, the invention provides methods for using such antisense oligonucleotides as analytical and diagnostic tools, as potentiators of transgenic plant and animal studies and gene therapy approaches, and as potential therapeutic agents.

Abstract: The invention encompasses tumorigenicity-inhibitiig antisense oligonucleotide sequences complementary to mRNA or double-stranded DNA that encodes mammalian DNA methyl transferase. It further encompasses methods for inhibiting tumorigenicity and pharmaceutical composition comprising the tumorigenicity-inhibiting antisense nucleotide.

Abstract: The invention encompasses tumorigenicity-inhibiting antisense oligonucleotide sequences complementary to mRNA or double-stranded DNA that encodes mammalian DNA methyl transferase. It further encompasses methods for inhibiting tumorigenicity and pharmaceutical composition comprises the tumorigenicity-inhibiting antisense nucleotide.